

Sino Biopharmaceutical Limited

Responsible Marketing Policy

1. Purpose

This policy aims to improve and strengthen the sustainable operation and development of Sino Biopharmaceutical Limited together with its subsidiaries (hereinafter referred to as ("the Group")), to ensure that the Group complies with the requirements of the relevant laws and regulations as well as business ethics when promoting and marketing the Group's products to stakeholders, and to demonstrate the Group's values of responsibility.

2. Applicability

The policy applies to the Group. All directors, management, and other employees, including the Group's full-time and part-time employees, must comply with the policy.

3. Basic Requirements of Drug Quality

The Group has set up a full-life circle quality management system under the direct leadership of the heads of member companies to ensure product quality and patient safety.

Comply with the drug label management regulations. The corresponding prompt or warning is printed in a prominent position in the package or instruction manual. Ingredients or excipients that may cause adverse reactions contained in the drug formulation, shall be clearly stated in the instructions.

Established a pharmacovigilance management system. Upon the adverse reactions caused by drugs of the Group are confirmed, we will report them to the competent drug regulatory authority in a timely manner and deal with them as per related regulations.

4. Marketing Principles and Internal Control

- Conduct legal, true, and accurate communication and publicity based on scientific facts, refrain from any false or misleading publicity, and ensure that

accurate and true drug information is conveyed to stakeholders.

- Provide drug information in accordance with the principles of appropriateness and accuracy. All marketing materials must comply with the requirements of the local regulations, based on the latest scientific and valid evidence, and shall not mislead the audience by means of misconstruction, exaggeration, overemphasis, neglect, or otherwise.
- Establish a strict internal control management system. All marketing activities or external interaction information, whether for promotion or non-promotion purposes, including content, methods, channels, etc., must comply with the Group's policies and go through the corresponding procedures. Only after approval can they be held or released externally to prevent liability risks such as misleading sales and selling unapproved drugs.
- Conduct regular marketing and sales audits at least once a year to ensure the accuracy and compliance of advertising and marketing activities, as well as legal compliance of sales and marketing practices.
- Any relevant party can whistleblow any behavior or individual that may violate national laws and regulations, current international business standards, and the Group's policies through the open whistleblowing channel, and the information of the whistleblowers shall be kept strictly confidential. All whistleblowing shall be registered, investigated and dealt with in accordance with the relevant procedures of the Group.
- All interactions with healthcare professionals and patient groups shall be compliant, transparent and consistent with medical ethics. No improper contributions shall be provided to healthcare professionals. Interactions including academic events and expert consultancy services shall be priced fairly with transparent report. Funding and consultancy fees shall not be linked to pharmaceutical product sales. Collaborations with patient organizations shall be limited to public welfare support and disease education, with the independent stance of organizations fully safeguarded.
- Clear boundaries shall be maintained between the promotion of prescription medicines and over-the-counter (OTC) medicines. Marketing of prescription medicines to consumers is prohibited. When directly promoting OTC medicines to consumers, approved health indications shall be fully and prominently

disclosed, covering both product benefits and all risks. Unsubstantiated efficacy claims that mislead consumers into self-diagnosis and self-medication are forbidden.

5. Customer Information Protection

Fully respect and protect the privacy and data of customers or consumers, and use management and technical means to prevent unauthorized access to or disclosure of customer information.

6. Regular Training

Conduct at least one responsible marketing training session covering all employees (including part-time) and contractors every year, enhance employees' awareness of compliance marketing, and achieve a level of competence with sufficient medical and professional knowledge to provide accurate and responsible drug information. Upon completion of training, relevant training records shall be properly filed, including but not limited to training materials, training schedules, attendance sheets or participant rosters.

7. Violation Reporting and Process

Any relevant party can whistleblow any behavior or individual that may violate national laws and regulations, current international business standards, and the Group's policies through the open whistleblowing channel (sjjcb@cttq.com) , and the information of the whistleblowers shall be kept strictly confidential. All whistleblowing shall be registered, investigated, and dealt with by the relevant procedures of the Group. Corrective measures will be taken if necessary, and the results of investigation and treatment will be reported to the whistleblowers.

8. Supplementary Provisions

The Policy is formulated, revised and interpreted by Sino Biopharmaceutical Limited, and shall take effect as of the date of issuance. Anything not covered in this policy, or contrary to the relevant laws, regulations, or normative documents of the People's Republic of China, should be implemented in accordance with the relevant laws, regulations, or normative documents of the People's Republic of China.